Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Issue of Equity

21 Jul 2006 07:00

ReGen Therapeutics PLC21 July 2006 ReGen Therapeutics Plc places 111,000,000 of shares ReGen Therapeutics Plc ("ReGen" or the "Company") announces that it has todayplaced through its brokers J M Finn & Co with new and existing shareholders111,000,000 new ordinary shares at 1p per share to raise £1,110,000, beforeexpenses ("Placing") Application will be made for these 111,000,000 new ordinary shares to beadmitted to the AIM Market of the London Stock Exchange Plc and dealings areexpected to commence at 8am on 27th July 2006. Executive Chairman Percy Lomax commented, "This money will be used for thecommercialisation of Colostrinin(TM)as per the recently announced deal withMetagenics Inc. and carry out further work on the development of its constituentpeptides as potential pharmaceuticals as well as providing additional resourcesfor the development of new formulations of zolpidem for the rehabilitation ofpeople with brain injury. This has received considerable positive publicity inthe national press and a documentary film is currently being discussed with anumber of producers. Depending upon the actual timing of anticipated revenuesfrom the commercialisation of ColostrininTM, the achievement of developmentmilestones and whether other commercial opportunities present themselves, it maybe necessary to raise additional amounts of capital in the future." All new ordinary shares will rank pari passu with the existing ordinary shares of 0.1p each in the Company. Two Non-Executive Directors are subscribing for new ordinary shares in theplacing: Mr Peter Garrod is subscribing for 2,500,000 new ordinary shares makinghis total holding 66,250,000 representing 9.54% of the enlarged share capital.Mr Keith Corbin is subscribing for 1,000,000 new ordinary shares making histotal holding 1,105,000 representing 0.16% of the enlarged share capital. For further information, please contact: Andrew MarshallGreycoat CommunicationsTel. 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th May 200610:51 amRNSResearch Update
15th Mar 200611:01 amRNSFinal Results
14th Feb 20067:00 amRNSAcquisition
8th Feb 200611:00 amRNSAcquisition
9th Jan 200611:00 amRNSResearch Update
10th Oct 200510:51 amRNSEGM Statement
28th Sep 20059:07 amRNSResearch Update
22nd Sep 20054:26 pmRNSHolding(s) in Company
20th Sep 200512:26 pmRNSHolding(s) in Company
15th Sep 20058:05 amRNSIssue of Equity
15th Sep 20058:00 amRNSShare Finance Facility
15th Sep 20057:48 amRNSInterim Results
6th Sep 200510:27 amRNSAcquisition of Rights
10th Aug 200511:03 amRNSGrant of US Patent
18th Jul 200510:20 amRNSChange of Adviser
27th Jun 20057:00 amRNSResearch Update
20th Jun 20057:01 amRNSResearch Update
13th Jun 200512:59 pmRNSDirector Shareholding
26th Apr 20051:08 pmRNSResult of AGM
26th Apr 200512:39 pmRNSAGM Statement
15th Mar 20054:53 pmRNSStatement re ADR's
8th Mar 200511:15 amRNSDirectorate Change
4th Mar 20057:00 amRNSResearch Update
14th Feb 200512:19 pmRNSHolding(s) in Company
14th Feb 20057:00 amRNSResearch Update
9th Feb 20057:00 amRNSFinal Results
7th Feb 20054:50 pmRNSHolding(s) in Company
1st Feb 200512:45 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.